Cargando…

A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing management or as monotherapy where it is deemed necessary. It has been found to be beneficial in improving β-cell function and glycemic control,...

Descripción completa

Detalles Bibliográficos
Autores principales: Eligar, Vinay S, Bain, Stephen C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770622/
https://www.ncbi.nlm.nih.gov/pubmed/24039399
http://dx.doi.org/10.2147/DDDT.S32331

Ejemplares similares